Details of the Drug Reposition

General Information of This Drug (ID: DMG0C81)

Drug Name
Deferoxamine   DMG0C81
Synonyms
deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; 70-51-9; Deferrioxamine; Deferoxamin; Deferoxaminum; DFOM; Desferin; Desferral; Desferrin; Desferex; Desferan; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; Desferriferrioxamin B; UNII-J06Y7MXW4D; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina ; Deferoxamine
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Subarachnoid hemorrhage DISI7I8Y 8B01 Approved [1]
Acute iron or aluminum toxicity DISU8V8B FB83.20 Approved [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 Deferoxamine FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207384.
3 ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health.